A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells

International Journal of Oncology

Volumn 35, Issue 6, 2009, Pages 1353-1360

  Jeong, Seung Hun ^a   Lee, Jee Suk ^a   Jeong, Na Young ^a   Kim, Tae Hyun ^a   Yoo, Ki Soo ^a   Song, Suhee ^b   Suh, Hongsuk ^b   Kwon, Taeg Kyu ^c   Park, Bong Soo ^b   Yoo, Young Hyun ^a  

^a Dong A University College of Medicine   (South Korea)

^b Pusan National University   (South Korea)

^c Keimyung University School of Medicine   (South Korea)

Author keywords

Apoptosis; Bcl 2; Caki 1; Nuclear bodies; Promyelocytic leukemia; Resveratrol

Indexed keywords

HS 1793; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN BCL 2; RESVERATROL; RESVERATROL DERIVATIVE; UNCLASSIFIED DRUG; 4 (6 HYDROXY 2 NAPHTHYL) 1,3 BENZENEDIOL; 4-(6-HYDROXY-2-NAPHTHYL)-1,3-BENZENEDIOL; ANTINEOPLASTIC AGENT; NAPHTHOL DERIVATIVE; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; RESORCINOL DERIVATIVE; STILBENE DERIVATIVE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS INCLUSION BODY; CELL STRAIN U937; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; CONFOCAL MICROSCOPY; DRUG RESISTANCE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; PATHOLOGY; PHYSIOLOGY; PROMYELOCYTIC LEUKEMIA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTRANUCLEAR INCLUSION BODIES; KIDNEY NEOPLASMS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, CONFOCAL; NAPHTHOLS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RESORCINOLS; STILBENES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 73949157709     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000453     Document Type: Article

References (41)

1. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 253: 615-627, 2002.
2. Lowenberg B, Downing JR and Burnett A: Acute myeloid leukemia. N Engl J Med 341: 1051-1062, 1999.
3. Smith M, Barnett M, Bassan R, Gatta G, Tondini C and Kern W: Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 50: 197-222, 2004.
4. Tomita Y, Bilim V, Kawasaki T, Takahashi K, Okan I, Magnusson KP and Wiman KG: Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53. Int J Cancer 66: 322-325, 1996.
5. Tsujimoto Y and Croce CM: Analysis of the structure, transcripts and protein products of Bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218, 1986.
6. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997.
7. Murph AN, Bredesen DN, Cortopassi G, Wang E and Fiskum G: Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci USA 93: 9893-9898, 1996.
8. Campos L, Rouault JP, Sabido O, et al: High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81: 3091-3096, 1993.
9. Yin DX and Schimke RT: Bcl-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 55: 4922-4928, 1995.
10. Park JW, Choi YJ, Suh SI, et al: Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. Carcinogenesis 22: 1633-1639, 2001.
11. Gusman J, Malonne H and Atassi G: A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis. 22: 1111-1117, 2001.
12. Frémont L: Biological effects of resveratrol. Life Sci 66: 663-673, 2000.
13. Kotha A, Sekharam M, Cilenti L, et al: Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 5: 621-629, 2006.
14. Woo KJ, Lee TJ, Lee SH, et al: Elevated gadd153/chop expression during resveratrol-induced apoptosis in human colon cancer cells. Biochem Pharmacol 73: 68-76, 2007.
15. Ulrich S, Wolter F and Stein JM: Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. Mol Nutr Food Res 49: 452-461, 2005.
16. Zhang W, Fei Z, Zhen HN, Zhang JN and Zhang X: Resveratrol inhibits cell growth and induces apoptosis of rat C6 glioma cells. J Neurooncol 81: 231-240, 2007.
17. Cecchinato V, Chiaramonte R, Nizzardo M, Cristofaro B, Basile A, Sherbet GV and Comi P: Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol 74: 1568-1574, 2007.
18. Clément MV, Hirpara JL, Chawdhury SH and Pervaiz S: Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92: 996-1002, 1998.
19. Lee EO, Kwon BM, Song GY, et al: Heyneanol A induces apoptosis via cytochrome c release and caspase activation in human leukemic U937 cells. Life Sci 74: 2313-2326, 2004.
20. Jeong SH, Jo WS, Song S, et al: A novel resveratrol derivative, HS-1793, overcome the resistance conferred by Bcl-2 in human leukemia U937 cells. Biochem Phamacol 77: 1337-1347, 2009.
21. Ruefli AA, Ausserlechner MJ, Bernhard D, et al: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98: 10833-10838, 2001.
22. Hofmann TG and Will H: Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ 10: 1290-1299, 2003.
23. Spector DL: Nuclear domains. J Cell Sci 114: 2891-2893, 2001.
24. Muratani M, Gerlich D, Janicki SM, Gebhard M, Eils R and Spector DL: Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nat Cell Biol 4: 106-110, 2002.
25. Chelbi-Alix MK, Pelicano L, Quignon F, et al: Induction of the PML protein by interferons in normal and APL cells. Leukemia 9: 2027-2033, 1995.
26. Kakizuka A, Miller HW Jr, Umesono K, et al: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66: 663-674, 1991.
27. Bernardi R and Pandolfi PP: Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22: 9048-9057, 2003.
28. Salomoni P and Pandolfi PP: The role of PML in tumor suppression. Cell 108: 165-170, 2002.
29. Pearson M and Pelicci PG: PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene 20: 7250-7256, 2001.
30. Negorev D and Maul GG: Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20: 7234-7242, 2001.
31. Li H and Chen JD: PML and the oncogenic nuclear domains in regulating transcriptional repression. Curr Opin Cell Biol 12: 641-644, 2000.
32. Lehembre F, Muller S, Pandolfi PP and Dejean A: Regulation of Pax3 transcriptional activity by SUMO-1-modified PML. Oncogene 20: 1-9, 2001.
33. Zhong S, Müller S, Ronchetti S, Freemont PS, Dejean A and Pandolfi PP: Role of SUMO-1-modified PML in nuclear body formation. Blood 95: 2748-2752, 2000.
34. Son SH, Yu E, Ahn Y, Choi EK, Lee H and Choi J: Retinoic acid attenuates promyelocytic leukemia protein-induced cell death in breast cancer cells by activation of the ubiquitin-proteasome pathway. Cancer Lett 247: 213-223, 2007.
35. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T and Jensen K: Regulation of p53 activity in nuclear bodies by a specific PML isoforms. EMBO J 19: 6185-6195, 2000.
36. Bode AM and Dong Z: Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805, 2004.
37. Pearson M: PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207-210, 2000.
38. Lallemand-Breitenbach V, Zhu J, Puvion F, et al: Role of promyelocytic leukemia (PML) SUMOlation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 193: 1361-1372, 2001.
39. La Morte VJ, Dyck JA, Ochs RL and Evans RM: Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc Natl Acad Sci USA 95: 4991-4996, 1998.
40. Zhu J, Koken MH, Quignon F, et al: Arsenic induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94: 3978-3983, 1997.
41. Gongora R, Stephan RP, Zhang Z and Cooper MD: An essential role for Daxx in the inhibition of B lymphopoiesis by type I interferons. Immunity 14: 727-737, 2001.